$LMAT climber $8.85 Website https://encryp
Post# of 35
Website
4/28/14
Q1 2015 results included:
Record sales of $18.9mm, +13% vs. Q1 2014
Operating income of $2.3mm vs. an operating loss of $0.2mm
Operating margin of 12%
Net income of $1.4mm vs. a net loss of $0.2mm
Earnings of $0.08 per diluted share vs. ($0.01)
EBITDA of $3.2mm vs. $0.6mm
Q1 2015 sales of $18.9mm increased 13% (+14% organic) vs. Q1 2014.
International sales increased 15%, while The Americas increased 12%
. XenoSure and the HYDRO LeMaitre Valvulotome were the primary drivers
of growth. Unit sales increased 12% in Q1 2015.
Gross margin increased to 69.2% in Q1 2015 from 67.0% in Q1 2014
largely due to XenoSure manufacturing efficiencies and price increases.
Shares Outstanding: 17.51M
Float: 9.54M
% Held by Insiders: 31.41%
% Held by Institutions: 36.30%
Shares Short (as of Mar 31, 2015): 40.86K
Short Ratio (as of Mar 31, 2015): 1.30
Short % of Float (as of Mar 31, 2015): 0.40%
Shares Short (prior month): 22.34K
Headlines